RIBOMETRIX Trademark

Trademark Overview


On Monday, November 20, 2023, a trademark application was filed for RIBOMETRIX with the United States Patent and Trademark Office. The USPTO has given the RIBOMETRIX trademark a serial number of 98278663. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, November 19, 2024. This trademark is owned by Ribometrix, Inc.. The RIBOMETRIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical prepara...

General Information


Serial Number98278663
Word MarkRIBOMETRIX
Filing DateMonday, November 20, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, November 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 24, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA and RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations that contain small molecule therapeutics that target RNA for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA and RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 3, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRibometrix, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDurham, NC 27709

Party NameRibometrix, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDurham, NC 27709

Trademark Events


Event DateEvent Description
Thursday, November 23, 2023NEW APPLICATION ENTERED
Wednesday, January 3, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 24, 2024ASSIGNED TO EXAMINER
Friday, June 28, 2024NON-FINAL ACTION E-MAILED
Friday, June 28, 2024NON-FINAL ACTION WRITTEN
Friday, June 28, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 31, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 31, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 22, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 4, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT